

**Supplementary material**

**Integrating Single Domain Antibodies into Field-Deployable Rapid Assays**

George P. Anderson, Lisa C. Shriver-Lake, Jinny L. Liu, and Ellen R. Goldman\*

US Naval Research Laboratory, Center for Biomolecular Science and Engineering, 4555  
Overlook Ave SW, Washington, DC 20375, USA

Table S1. Tail names and amino acid sequences

Table S2. Sequences of sdAb used in the VFA

Figure S1. Evaluation of different ACVE capture formats

Figure S2. Evaluation of two ACVE-based constructs on AuNPs

**Table S1.** Tail names and amino acid sequences

| Tail name                    | Tail sequence  |
|------------------------------|--|
| Hop tail                     | GAGGSGGAPASNRCSCQGSCWN   |
| Spy tag (ST)                 | AHIVMVDAYKPTK  |
| Gold binding peptide (gbp) 1 | MHGKTQATSGTIQS   |
| Gbp2                         | LKAHLPPSRLPS   |
| Synthetic zipper (synzip) 5  | NTVKELKNYIQELEERNAELKNLKEHLKFAKAELEFELAAHKFE   |
| synzip 6                     | QKVAQLKNRVAYKLKENAKLENIVARLENDNANLEKDIANLEKDIANLERDVAR   |
| synzip 17                    | NEKEELKSKKAELRNRIEQLKQKREQLKQKIANLRKEIEAYK   |
| synzip 18                    | SIAATLENDLARLENENARLEKDIANLERDLAKLEREEAYF  |
| E34                          | ITIRAAFLEKENTALRTEIAELEKEVGRSENIHSVSKYETRYGPL  |
| Rhizavidin (RZ)              | FDASNFKDFSSIASASSSWQNQSGSTMIIQVDSFGNVSGQVNRAQGTGCQN<br>SPYPLTGRVNGTFIAFSVGWNNSTENCNSATGWTGYAQVNNGNTEIVTSWNL<br>AYEGGSGPAIEQGQDTFQYVPTTENKSLLKD |

**Table S2.** Sequences of sdAb used in the VFA

| SdAb name | SdAb sequence   |
|-----------|---|
| ACVE      | DVQLVESGGGLVQPGGSLRLTCAASGLIFGSYAMGWFRQAPGKAREFVAASIWSGGDTYADSVK<br>GRFTISRDNAKNTVYLQMNSLEPEDTAVYSCAVGSKYISKDAKDYGYWGQGTQTVSS     |
| A3H2      | EVQLVESGGGLVQAGDSLRLSCTASGRISRAVMGWFRQAPGKEREFAAISAAPGTAYYAFYADS<br>VRGRFIISADSAKNTVYLQMNSLKPEDTAVYYCAADLKMQVAAYMNQRSDYWGQGTQTVSS |
| D12f      | EVQLQASGGGLVQDGGSRLSCAVAGRPLSDYGVGVWFRQASGKEREFAVISGSGIVTDYANSVK<br>GRFTISRDVAKNVVHLQMNSLKPEDTAVYYCAALTNPVYAAARSNSNDYGYWGQGTQTVSS |
| F6H2Y     | QVQLVESGGGLVQAGGSLRLSCATSGGTFSYGMGWFRQAPGKEREFAAIRRNGNGNGIEYA<br>DSVKGRFTISRDNAKNTVYLQMNSLTPEDTAVYYCAASISGYAYNTIERYNYWGQGTQTVSS   |
| E2        | EVQLQASGGGLVQAGGSLRLSCAASGRTDSTQHMAWFHQAPGKEREFTAIQWRGGGTSYTD<br>VKGRFTISRDNAKNTYLEMNSLKPEDTAVYYCATNTRWTFSPTRPDYWGQGTQTVSS        |
| C2        | EVQLQASGGGLVRPGGSLRLSCAASGFTSSYAMMWVRQAPGKGLEWVSAINGGGSTSADS<br>VKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCAKYQAAVHQEKEDYWGQGTQTVSS         |
| B6        | EVQLQASGGGLVQAGDSLRLSCAVSGRTISTFAMGWFRQAPGKEREFTVATINWSGSSARYADPV<br>EGRFTISRDDAKNTVYLEMSSLKPGDSAVYYCASGRYLGGITSYQGDFAPWGQGTQTVSS |

**Figure S1.**



Evaluation of different ACVE capture formats. Upper left spot = ACVE; upper right spot = ACVE-ACVE; lower left spot = SCVE-ST; lower right spot = ACVE-synthetic zipper 17

**Figure S2.**



Evaluation of two ACVE-based constructs on AuNPs. Left is ACVE-hop and right is the trivalent construct ACVE-ACVE-ACVE. Miriad test cartridges were spotted with a monoclonal anti-SEB (mAb 2F2) on the top, and SEBv on the bottom. Next 100  $\mu$ L of SEBv (10  $\mu$ g/mL) was applied to the cartridge, followed by a wash and the AuNPs. Cartridges were washed again and photographed.